Integrity Applications Signs Distribution Agreement for Its GlucoTrack Glucose Monitoring Device

Integrity Applications Inc. has entered into an exclusive distribution agreement with CuraTec Nordic, a Scandinavian medical device distributor.
 
The agreement will open crucial sales channels in Denmark, Sweden, Finland, and Norway for GlucoTrack, the company’s non-invasive glucose monitor for people with type 2 diabetes and pre-diabetes. According to the International Diabetes Federation, as of 2017, there are an estimated 1.55 million adults living with diabetes in the Nordic countries, and the vast majority of these patients have type 2 diabetes. The agreement became effective on July 3, 2018.
 
CuraTec Nordic, based in Copenhagen, is a privately held company focused entirely on innovative solutions for people with chronic conditions.
 
Kim Frederiksen, the CEO of CuraTec Nordic, said, “We have years of experience in helping patients manage their diabetes and we are excited about introducing GlucoTrack to the marketplace. We see GlucoTrack as part of our commitment to deliver innovative technologies that can help people with diabetes manage their condition in a better and smarter way.”
 
Curatec Nordic has strong relationships with key opinion leaders and diabetes treatment centers, experienced sales people that focus on treating physicians and diabetes nurses, strong patient support through their efficient call center, and key partnerships with patient associations.
 
Given CuraTec Nordic’s experience with blood glucose monitoring devices, Integrity believes it is the ideal partner to best manage sales execution and customer support for GlucoTrack in the Nordic countries.
 
David Podwalski, Integrity’s chief commercial officer, commented, “This distribution agreement is yet another milestone on our path to commercializing GlucoTrack. We are excited to work with Curatec Nordic to launch GlucoTrack in the Nordic countries. We believe that there is a tremendous need for a non-invasive device like GlucoTrack that will enable people with diabetes to test more frequently and to manage their diabetes more effectively.”
 
The commercialization of GlucoTrack in Europe is one of Integrity’s near-term priorities. The company has previously signed a distribution agreement for the Netherlands, and through its distributor is in discussions with local insurance companies for reimbursement of GlucoTrack. The Nordic countries represent an important next step in the company’s commercialization across Europe.
 
John Graham, CEO of Integrity Applications, said, “As we are seeing the progress in the Netherlands, we are confident that our new commercial strategy in partnership with strong local distributors will allow many more patients to benefit from improved diabetes management with GlucoTrack.”
 
GlucoTrack is a non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain. GlucoTrack features a small sensor that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time.
 
GlucoTrack has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2 diabetes and pre-diabetics, and is currently in the early stages of commercialization in Europe, South Korea, and other geographies. GlucoTrack is expected to begin clinical trials for U.S. Food and Drug Administration approval. The product is currently experimental in the United States and is limited to investigational use only.
 
Integrity Applications Inc. was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The company has developed GlucoTrack, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.